search reports
Categories
Categories

EPIOMIC EPIDEMIOLOGY SERIES: ALPHA-1 ANTI-TRYPSIN DEFICIENCY FORECAST IN 18 MAJOR MARKETS 2018–2028

Report Code : lhc-bsa0308
Published Date : 01 September, 2018 | No of Pages: 52

  • Report Description
  • Table of Contents
  • Related Reports
Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Alpha-1 Anti-Trypsin Deficiency Forecast in 18 Major Markets
Alpha-1 anti-trypsin deficiency (AATD) is an inherited, rare condition that causes a complete or partial reduction in the activity of alpha-1 anti-trypsin (AAT) in blood and lungs, which leads to the deposition of excessive abnormal AAT protein in liver cells. AAT protects tissues from enzymes produced by inflammatory cells, especially neutrophil elastase. In its absence (such as in alpha 1-anti-trypsin deficiency), neutrophil elastase is free to break down elastin, which contributes to the elasticity of the lungs. This results in respiratory complications, such as COPD (chronic obstructive pulmonary disease) in adults and cirrhosis of the liver in adults or children.
This report provides the current prevalent population for AATD across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, AATD patients grouped by comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of AATD include:
• Cirrhosis
• COPD
• Lung Cancer
• Asthma
• Panniculitis
• Systemic Vasculitis
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Ability to quantify patient populations in global AATD market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of AATD and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding of the impact of specific co-morbid conditions on the prevalent population of AATD patients.
• Identification of AATD patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of AATD patients.
Epiomic Epidemiology Series: Alpha-1 Anti-Trypsin Deficiency Forecast in 18 Major Markets 2018–2028

CONTENTS

• LIST OF TABLES AND FIGURES
• INTRODUCTION
• CAUSE OF THE DISEASE
• RISK FACTORS & PREVENTION
• DIAGNOSIS OF THE DISEASE
• VARIATION BY GEOGRAPHY/ETHNICITY
• DISEASE PROGNOSIS & CLINICAL COURSE
• KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
• METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
• TOP-LINE PREVALENCE FOR ALPHA-1 ANTI-TRYPSIN DEFICIENCY
• COMORBIDITIES OF ALPHA-1 ANTI-TRYPSIN DEFICIENCY PATIENTS
• ABBREVIATIONS USED IN THE REPORT
• OTHER BLACK SWAN SERVICES & SOLUTIONS
• REPORTS & PUBLICATIONS
• ONLINE EPIDEMIOLOGY DATABASES
• ONLINE PHARMACEUTICAL PRICING DATABASE
• REFERENCES
• APPENDIX

LIST OF TABLES AND FIGURES

• Table 1. Prevalence of AATD, total (000s)
• Table 2. Prevalence of AATD, males (000s)
• Table 3. Prevalence of AATD, females (000s)
• Table 4. AATD patients with cirrhosis, total (000s)
• Table 5. AATD patients with COPD, total (000s)
• Table 6. AATD patients with lung cancer, total (000s)
• Table 7. AATD patients with asthma, total (000s)
• Table 8. AATD patients with panniculitis, total (000s)
• Table 9. AATD patients with systemic vasculitis, total (000s)
• Table 10. Abbreviations and acronyms used in the report
• Table 11. USA prevalence of AATD by 5-yr age cohort, males (000s)
• Table 12. USA prevalence of AATD by 5-yr age cohort, females (000s)
• Table 13. Canada prevalence of AATD by 5-yr age cohort, males (000s)
• Table 14. Canada prevalence of AATD by 5-yr age cohort, females (000s)
• Table 15. France prevalence of AATD by 5-yr age cohort, males (000s)
• Table 16. France prevalence of AATD by 5-yr age cohort, females (000s)
• Table 17. Germany prevalence of AATD by 5-yr age cohort, males (000s)
• Table 18. Germany prevalence of AATD by 5-yr age cohort, females (000s)
• Table 19. Italy prevalence of AATD by 5-yr age cohort, males (000s)
• Table 20. Italy prevalence of AATD by 5-yr age cohort, females (000s)
• Table 21. Spain prevalence of AATD by 5-yr age cohort, males (000s)
• Table 22. Spain prevalence of AATD by 5-yr age cohort, females (000s)
• Table 23. UK prevalence of AATD by 5-yr age cohort, males (000s)
• Table 24. UK prevalence of AATD by 5-yr age cohort, females (000s)
• Table 25. Poland prevalence of AATD by 5-yr age cohort, males (000s)
• Table 26. Poland prevalence of AATD by 5-yr age cohort, females (000s)
• Table 27. Netherlands prevalence of AATD by 5-yr age cohort, males (000s)
• Table 28. Netherlands prevalence of AATD by 5-yr age cohort, females (000s)
• Table 29. Russia prevalence of AATD by 5-yr age cohort, males (000s)
• Table 30. Russia prevalence of AATD by 5-yr age cohort, females (000s)
• Table 31. Turkey prevalence of AATD by 5-yr age cohort, males (000s)
• Table 32. Turkey prevalence of AATD by 5-yr age cohort, females (000s)
• Table 33. Japan prevalence of AATD by 5-yr age cohort, males (000s)
• Table 34. Japan prevalence of AATD by 5-yr age cohort, females (000s)
• Table 35. South Korea prevalence of AATD by 5-yr age cohort, males (000s)
• Table 36. South Korea prevalence of AATD by 5-yr age cohort, females (000s)
• Table 37. India prevalence of AATD by 5-yr age cohort, males (000s)
• Table 38. India prevalence of AATD by 5-yr age cohort, females (000s)
• Table 39. Australia prevalence of AATD by 5-yr age cohort, males (000s)
• Table 40. Australia prevalence of AATD by 5-yr age cohort, females (000s)
• Table 41. Brazil prevalence of AATD by 5-yr age cohort, males (000s)
• Table 42. Brazil prevalence of AATD by 5-yr age cohort, females (000s)
• Table 43. Mexico prevalence of AATD by 5-yr age cohort, males (000s)
• Table 44. Mexico prevalence of AATD by 5-yr age cohort, females (000s)
• Table 45. Argentina prevalence of AATD by 5-yr age cohort, males (000s)
• Table 46. Argentina prevalence of AATD by 5-yr age cohort, females (000s)
Market Intel Report EPIOMIC EPIDEMIOLOGY SERIES: TESTICULAR CANCER FORECAST IN 24 MAJOR MARKETS 2018–2028
By: Black Swan Analysis Ltd | Published Date : 01 January, 2018 | No of Pages : 68
Market Intel Report EPIOMIC EPIDEMIOLOGY SERIES: THYROID CANCER FORECAST IN 21 MAJOR MARKETS 2018–2028
By: Black Swan Analysis Ltd | Published Date : 01 January, 2018 | No of Pages : 76
Market Intel Report EPIOMIC EPIDEMIOLOGY SERIES: ALLERGIC RHINITIS FORECAST IN 26 MAJOR MARKETS 2018–2028
By: Black Swan Analysis Ltd | Published Date : 01 January, 2018 | No of Pages : 88
Market Intel Report EPIOMIC EPIDEMIOLOGY SERIES: PRIMARY CARNITINE DEFICIENCY FORECAST IN 19 MAJOR MARKETS 2018–2028
By: Black Swan Analysis Ltd | Published Date : 01 January, 2018 | No of Pages : 58
Market Intel Report EPIOMIC EPIDEMIOLOGY SERIES: STROKE FORECAST IN 19 MAJOR MARKETS 2018–2028
By: Black Swan Analysis Ltd | Published Date : 01 January, 2018 | No of Pages : 108
Please select License
Single User Price:$ 5800
Site License Price:$ 8700
Enterprise Price:$ 10400